Blog

Blog

Drug Target Encyclopedia Series (29) —CD142

Linkedin

Release Time：

2026-01-20 13:52

 

  CD142, also known as Tissue Factor (TF), is a transmembrane glycoprotein that serves as the primary initiator of the extrinsic coagulation cascade. Beyond hemostasis, CD142 plays a pivotal role in thrombosis, cancer progression, inflammation, and vascular pathology, making it a high-value membrane protein target across multiple therapeutic areas.

Target Definition

  • Protein name: CD142 / Tissue Factor
  • Localization: Cell membrane
  • Function: Binds Factor VII/VIIa → activates downstream coagulation signaling
  • Non-canonical roles: Cell signaling, angiogenesis, metastasis, tumor–stroma crosstalk

Disease & Drug Value

CD142 is aberrantly expressed or activated in multiple high-burden diseases:

Thrombosis & Coagulation Disorders

  • Pathological clot formation
  • Sepsis-associated coagulopathy
  • Disseminated intravascular coagulation (DIC)

Oncology

  • Overexpressed in many solid tumors (e.g., pancreatic, glioma, breast)
  • Correlates with:
    • Tumor aggressiveness
    • Metastatic potential
    • Cancer-associated thrombosis

Inflammation & Vascular Disease

  • Crosstalk between coagulation and inflammatory signaling
  • Endothelial dysfunction and vascular injury

👉 These features position CD142 as a bridge target connecting coagulation biology with cancer and inflammation therapeutics.

🚀 Emerging Therapeutic Strategies

🧪 Monoclonal antibodies

  • Neutralizing TF activity
  • Blocking TF–FVIIa complex formation
  • Antibody–drug conjugates (TF-ADC) for tumor-selective killing

🧪 Small-molecule & biologics

  • Inhibitors targeting downstream coagulation signaling
  • Modulation of TF-driven PAR signaling pathways

🧪 Cell & gene-based approaches

  • mRNA tools to transiently express or modulate CD142
  • Target validation in cancer and thrombosis models
  • Safer, controllable expression for mechanistic studies

⚠️ Key Challenges

  • Balancing antithrombotic efficacy vs. bleeding risk
  • Tumor-selective targeting without systemic coagulation disruption
  • Complex biology spanning coagulation, immunity, and cancer signaling

🔍 Industry Outlook

CD142 is increasingly viewed as:

  • A dual-function therapeutic target (coagulation + oncology)
  • A biomarker for cancer-associated thrombosis
  • A strategic entry point for next-generation ADCs and RNA-based research platforms

As precision medicine advances, CD142-centered strategies are expected to expand across oncology, rare coagulation disorders, and inflammatory diseases.

Need CD142 tools for your research?

 

Fill out the form below, or visit the link: to browse the complete list of available in-stock products.  

 

Prev

Drug Target Encyclopedia Series (30) —PTK7

Drug Target Encyclopedia Series (28) —FOLR1

Next